<p>H.C. Wainwright 的分析师 Patrick Trucchio 今天重申了对 Oncolytics Biotech 的买入评级，并设定了 10.00 美元的目标价。</p>
<h3>在 TipRanks Premium 上享受 50% 的折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Patrick Trucchio 给出买入评级的原因是多种因素的结合，突显了 Oncolytics Biotech 的 pelareorep (pela) 在满足肿瘤学未满足需求方面的潜力，特别是在难治性结直肠癌 (mCRC) 中。将 pela 推进到 KRAS 突变转移性结直肠癌的自我赞助随机试验的决定反映了 Oncolytics 对其疗效的信心，基于强有力的临床和转化数据，包括其超越当前治疗标准的能力。</p>
<p>此外，早期试验的数据表明，与历史基准相比，KRAS 突变 MSS mCRC 患者的反应率、无进展生存期和总体生存期均令人印象深刻。转化研究结果还表明免疫激活和肿瘤对免疫治疗的敏感性，使 pela 成为改善 MSS mCRC 结果的有希望的候选者，该人群对现有疗法大多具有抵抗性。随着多个即将进行的试验计划和 pela 的巨大商业机会，Trucchio 认为该股票有望创造显著的价值，强化了他的 10 美元目标价。</p>
<p>在今天发布的另一份报告中，Lake Street 也维持了该股票的买入评级，目标价为 7.00 美元。</p>

Oncolytics生物科技

<p>H.C. Wainwright 的分析师 Patrick Trucchio 重申了对 Oncolytics Biotech 的买入评级，指出 pelareorep 在 KRAS 突变的 MSS 结直肠癌中的潜力。预计该股票将创造显著价值，目标价为 10 美元。Lake Street 也维持了买入评级，目标价为 7 美元。Pelareorep 在改善 MSS mCRC（对现有疗法具有抵抗力的人群）的治疗效果方面显示出希望</p>

<p>H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Oncolytics Biotech today and set a price target of $10.00.</p>
<div class="lb-trans"><p>H.C. Wainwright 的分析师 Patrick Trucchio 今天重申了对 Oncolytics Biotech 的买入评级，并设定了 10.00 美元的目标价。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>在 TipRanks Premium 上享受 50% 的折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Patrick Trucchio has given his Buy rating due to a combination of factors that highlight the potential of Oncolytics Biotech’s pelareorep (pela) in addressing unmet needs in oncology, particularly in hard-to-treat colorectal cancer (mCRC). The decision to advance pela into a self-sponsored randomized trial in KRAS-mutant metastatic colorectal cancer reflects Oncolytics’ confidence in its efficacy based on strong clinical and translational data, including its ability to outperform current treatment standards.</p>
<div class="lb-trans"><p>Patrick Trucchio 给出买入评级的原因是多种因素的结合，突显了 Oncolytics Biotech 的 pelareorep (pela) 在满足肿瘤学未满足需求方面的潜力，特别是在难治性结直肠癌 (mCRC) 中。将 pela 推进到 KRAS 突变转移性结直肠癌的自我赞助随机试验的决定反映了 Oncolytics 对其疗效的信心，基于强有力的临床和转化数据，包括其超越当前治疗标准的能力。</p>
</div><p>Furthermore, data from earlier trials demonstrated impressive response rates, progression-free survival, and overall survival in KRAS-mutant MSS mCRC patients compared to historical benchmarks. Translational findings also suggest immune activation and tumor sensitization to immunotherapy, positioning pela as a promising candidate for improving outcomes in MSS mCRC, a population largely resistant to existing therapies. With multiple upcoming trials planned and the substantial commercial opportunity for pela, Trucchio believes the stock is poised for significant value creation, reinforcing his $10 price target.</p>
<div class="lb-trans"><p>此外，早期试验的数据表明，与历史基准相比，KRAS 突变 MSS mCRC 患者的反应率、无进展生存期和总体生存期均令人印象深刻。转化研究结果还表明免疫激活和肿瘤对免疫治疗的敏感性，使 pela 成为改善 MSS mCRC 结果的有希望的候选者，该人群对现有疗法大多具有抵抗性。随着多个即将进行的试验计划和 pela 的巨大商业机会，Trucchio 认为该股票有望创造显著的价值，强化了他的 10 美元目标价。</p>
</div><p>In another report released today, Lake Street also maintained a Buy rating on the stock with a $7.00 price target.</p>
<div class="lb-trans"><p>在今天发布的另一份报告中，Lake Street 也维持了该股票的买入评级，目标价为 7.00 美元。</p>
</div>

Oncolytics 生物科技的 Pelareorep 在 KRAS 突变 MSS 结直肠癌中的良好潜力推动了买入评级